Bionomics Limited (BNO) has been granted its key patent (US 8,198,466) relating to its vascular disrupting agent BNC105 by the United States Patent and Trademark Office. This patent is at the centre of the BNC105 patent portfolio. The patent is valid for 20 years to February 2027. BNC105 patents have been filed in each of the major pharmaceutical markets. Granting of this patent has already occurred in Australia and New Zealand.
CEO and Managing Director of Bionomics Dr Deborah Rathjen said the granting of this patent in the US is a milestone in Bionomics’ patent strategy for the BNC105 program. “This solidifies our intellectual property protection for Bionomics’ lead oncology clinical stage asset. The granted patent provides a substantial value-add for the BNC105 program and strengthens our partnering data package.” Bionomics has also filed a patent application for the manufacture of BNC105. Bionomics owns additional patents and has applications covering vascular disrupting agents related to BNC105, together with methods of treatment of cancer both as monotherapy and in combination with selected therapies.
Bionomics (BNO) is a leading international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, Alzheimer’s disease, epilepsy and multiple sclerosis.BNC105, which is undergoing clinical development for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. Bionomics’ discovery and development activities are driven by its three technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels). MultiCore® is Bionomics’ proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system.